Distinguished Cancer Researcher Stuart S. Martin, PhD, Appointed Chair of Pharmacology & Physiology at UM School of Medicine

Stuart S. Martin, PhD, a pioneering figure in breast cancer research, has been officially appointed Chair of the Department of Pharmacology & Physiology at the University of Maryland School of Medicine (UMSOM). This appointment marks a significant milestone at UMSOM, reflecting Dr. Martin’s exceptional contributions to cancer biology and translational research. Having served as Interim Chair for the past year, Martin’s leadership is set to further propel the department’s scientific advancements, particularly in the realm of targeted drug development and metastatic cancer therapeutics.

Dr. Martin is internationally recognized for his groundbreaking discovery of microtentacles — thin, dynamic membrane protrusions found on the surface of breast cancer cells. These structures play a critical role in facilitating metastasis, the process by which cancer spreads to distant organs. This discovery has significantly deepened the oncology community’s understanding of tumor cell biology and opened new avenues for therapeutic intervention aimed at halting cancer dissemination at its earliest stages.

A hallmark of Dr. Martin’s recent work includes the invention of the TetherChip device, a novel microfluidic platform designed to preserve and analyze circulating tumor cells (CTCs) without disrupting vital structural features such as microtentacles. The TetherChip operates by preventing cell adhesion during sample processing, which historically compromised the integrity of these delicate structures. With a robust shelf life exceeding two years, this innovative device enables rapid and reliable testing of tumor biopsies, potentially allowing patients to receive diagnostic insights on the day of their biopsy procedure—a critical advancement toward personalized oncology.

Dr. Martin’s scientific inquiry focuses on the bioengineering and molecular characterization of tumor cell behaviors that underlie metastatic competence. His laboratory employs cutting-edge techniques that blend cellular biophysics, advanced imaging, and molecular pharmacology to delineate mechanisms that can be targeted pharmacologically. Supported by over $20 million in competitive funding from the National Cancer Institute, Department of Defense, and multiple cancer foundations, his research program is at the forefront of bridging fundamental science and clinical application.

In addition to his research accomplishments, Dr. Martin holds the prestigious Drs. Angela and Harry Brodie Professorship of Translational Cancer Research. This endowed position honors the legacy of Dr. Brodie, whose pioneering work on aromatase inhibitors dramatically transformed breast cancer therapeutics. Martin’s role as Deputy Director of the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) further underscores his integral contribution to orchestrating multidisciplinary collaborative efforts aimed at advancing cancer treatment modalities.

A significant administrative achievement under Dr. Martin’s stewardship has been the successful merger of UMSOM’s Department of Pharmacology and Department of Physiology into a cohesive interdisciplinary unit. This consolidation harmonizes expertise across cancer therapeutics, molecular physiology, and neuropharmacology, fostering synergistic research initiatives. The unified department benefits from strategic partnerships with UMSOM’s various centers and institutes, as well as its proximity to the innovative BioPark property at 4MLK, a hub for biomedical entrepreneurship and translational research.

Dr. Martin’s prolific academic output includes over 90 peer-reviewed publications in distinguished journals such as Cancer Research, Proceedings of the National Academy of Sciences (PNAS), and Nature Communications. His work has accrued nearly 5,000 citations, reflecting the high impact and broad recognition of his contributions within the scientific community. His h-index of 42 is a testament to his sustained influence on the field of metastatic breast cancer biology.

His commitment to mentorship and education has been acknowledged with notable awards, including the Dr. Patricia K. Sokolove Outstanding Mentor Award and the GPILS Teacher of the Year Award, both highly valued recognitions from UMSOM graduate students. These accolades highlight Dr. Martin’s dedication to nurturing the next generation of scientists and fostering a collaborative research milieu conducive to intellectual growth and innovation.

Dr. Martin’s research trajectory illustrates a seamless integration of fundamental and translational sciences, from elucidating cellular mechanisms to developing clinical tools like the TetherChip. Efforts to obtain FDA approval for this device are ongoing and represent a promising step toward clinical implementation, potentially revolutionizing how metastatic potential is assessed in breast cancer patients. This innovation not only enhances diagnostic precision but also opens pathways for targeted therapies that intervene in metastatic processes.

In his role as Chair, Dr. Martin envisions an environment where scientific inquiry is driven by cross-disciplinary collaborations. He emphasizes the importance of integrating insights from physiology, pharmacology, and cancer biology to develop novel therapeutic interventions that address a broad spectrum of medical conditions. His leadership is anticipated to amplify UMSOM’s contributions to biomedical research and catalyze the translation of basic science discoveries into impactful clinical applications.

Dr. Martin’s early research training included a PhD in biomedical sciences from the University of California, San Diego, enriched by a Howard Hughes undergraduate research fellowship at the University of Virginia. He further honed his expertise during a Damon Runyon postdoctoral fellowship at Harvard Medical School, where he combined genomic studies with murine models of breast tumor metastasis under the mentorship of Dr. Phil Leder. This rigorous foundation laid the groundwork for his innovative approach to cancer metastasis research.

Beyond his research and administrative roles, Dr. Martin is actively engaged in the broader oncology community. He serves as Chair of the American Cancer Society Board for the Baltimore/DC Region and is a member of the American Association for Cancer Research. These affiliations underscore his commitment to advocacy, education, and fostering partnerships that support cancer research and patient care at multiple levels.

In summary, Stuart S. Martin, PhD, embodies the quintessential leader in translational cancer research, seamlessly blending scientific ingenuity with visionary departmental stewardship. His appointment as Chair of Pharmacology & Physiology at the University of Maryland School of Medicine promises to accelerate advances in the understanding and treatment of metastatic breast cancer, with transformative implications for patients worldwide.

News Publication Date: 2024

Web References:
https://www.medschool.umaryland.edu/profiles/martin-stuart/
https://www.umms.org/umgccc
https://www.medschool.umaryland.edu/news/2020/um-school-of-medicine-researchers-develop-novel-test-for-microtentacles-on-breast-cancer-cells.html